|
Brain Neoplasms
|
0.030 |
Biomarker
|
group |
BEFREE |
Leucine-rich repeat containing G protein-coupled receptor 5 (LGR5), one of the target genes of the Wnt signaling pathway, has recently been identified as a marker for brain cancer stem-like cells.
|
24172981 |
2014 |
|
Malignant neoplasm of brain
|
0.020 |
Biomarker
|
disease |
BEFREE |
Leucine-rich repeat containing G protein-coupled receptor 5 (LGR5), one of the target genes of the Wnt signaling pathway, has recently been identified as a marker for brain cancer stem-like cells.
|
24172981 |
2014 |
|
Malignant neoplasm of colon and/or rectum
|
0.100 |
Biomarker
|
disease |
BEFREE |
LGR5 positivity defines stem-like cells in colorectal cancer.
|
24282287 |
2014 |
|
Carcinogenesis
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
Lgr5(+) cells were found more frequently in low-grade tumors with active Wnt signaling and an intestinal gland type, suggesting that LGR5 is likely involved in the very early stages of Wnt-driven tumorigenesis in the stomach.
|
24340024 |
2013 |
|
Neoplasm Metastasis
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
Leucine-rich repeat-containing G-protein-coupled receptor 5 was correlated with invasion and metastasis.
|
24594994 |
2014 |
|
Carcinoma
|
0.030 |
AlteredExpression
|
group |
BEFREE |
Leucine-rich repeat-containing G-protein-coupled receptor 5 expression was significantly higher in gastric carcinomas than in normal mucosa.
|
24594994 |
2014 |
|
Tumor Cell Invasion
|
0.100 |
AlteredExpression
|
phenotype |
BEFREE |
Leucine-rich repeat-containing G-protein-coupled receptor 5 expression positively correlated with the depth of invasion, lymph node metastasis, distance of metastasis, and MMP2 expression levels.
|
24594994 |
2014 |
|
Small cell carcinoma of esophagus
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
Lgr5 was expressed in SCCE cancer tissues.
|
24666414 |
2014 |
|
Tumor Progression
|
0.090 |
AlteredExpression
|
phenotype |
BEFREE |
Lgr5 over-expression is positively related to the tumor progression and HER2 expression in stage pTNM IV colorectal cancer.
|
24817953 |
2014 |
|
Malignant neoplasm of colon and/or rectum
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Lgr5 over-expression is positively related to the tumor progression and HER2 expression in stage pTNM IV colorectal cancer.
|
24817953 |
2014 |
|
Malignant Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Lgr5-positive cells are cancer stem cells in skin squamous cell carcinoma.
|
25135431 |
2014 |
|
Primary malignant neoplasm
|
0.100 |
Biomarker
|
group |
BEFREE |
Lgr5-positive cells are cancer stem cells in skin squamous cell carcinoma.
|
25135431 |
2014 |
|
Cervix carcinoma
|
0.030 |
Biomarker
|
disease |
BEFREE |
Lgr5 may play an important role in the development and progression of cervical carcinoma, and may be a potential therapeutic target for the treatment of cervical carcinoma.
|
25973068 |
2015 |
|
Tumor Progression
|
0.090 |
Biomarker
|
phenotype |
BEFREE |
Lgr5, which is a somatic stem cell biomarker, plays an important role during the carcinogenesis and tumor progression.
|
26077638 |
2016 |
|
Malignant Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Leucine-rich repeat-containing G-protein-coupled receptor 5 (LGR5) is a cancer stem cell marker and a down-stream target in Wnt/β-catenin signaling.
|
26416247 |
2015 |
|
Primary malignant neoplasm
|
0.100 |
Biomarker
|
group |
BEFREE |
Leucine-rich repeat-containing G-protein-coupled receptor 5 (LGR5) is a cancer stem cell marker and a down-stream target in Wnt/β-catenin signaling.
|
26416247 |
2015 |
|
Secondary Neoplasm
|
0.020 |
Biomarker
|
group |
BEFREE |
LGR5 may serve as a future potential biomarker for patient risk stratification and loco regional metastases in PTC.
|
26416247 |
2015 |
|
Primary malignant neoplasm
|
0.100 |
Biomarker
|
group |
BEFREE |
LGR5 is a marker of normal and cancer stem cells in various tissues where it functions as a receptor for R-spondins and increases canonical Wnt signalling amplitude.
|
26517508 |
2015 |
|
Malignant Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Lgr5 Methylation in Cancer Stem Cell Differentiation and Prognosis-Prediction in Colorectal Cancer.
|
26599100 |
2015 |
|
Primary malignant neoplasm
|
0.100 |
Biomarker
|
group |
BEFREE |
Lgr5 Methylation in Cancer Stem Cell Differentiation and Prognosis-Prediction in Colorectal Cancer.
|
26599100 |
2015 |
|
Malignant Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Lgr5 has recently been identified as a reliable biomarker of cancer stem cells (CSCs) in colorectal cancer (CRC); however, its prognostic value is still controversial.
|
26758198 |
2016 |
|
Primary malignant neoplasm
|
0.100 |
Biomarker
|
group |
BEFREE |
Lgr5 has recently been identified as a reliable biomarker of cancer stem cells (CSCs) in colorectal cancer (CRC); however, its prognostic value is still controversial.
|
26758198 |
2016 |
|
Carcinoma, Basal Cell
|
0.030 |
AlteredExpression
|
disease |
BEFREE |
LGR5 expression is controled by IKKα in basal cell carcinoma through activating STAT3 signaling pathway.
|
27049829 |
2016 |
|
Experimental Organism Basal Cell Carcinoma
|
0.010 |
AlteredExpression
|
phenotype |
BEFREE |
LGR5 expression is controled by IKKα in basal cell carcinoma through activating STAT3 signaling pathway.
|
27049829 |
2016 |
|
Malignant Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Leucine-rich repeat-containing G-protein-coupled receptor 5 (LGR5) is a target of Wnt signalling and considered both a cancer stem cell marker and intestinal stem cell marker.
|
27140312 |
2016 |